Scancell to produce and validate T cell redirecting bispecific antibodies

Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. 

The UK company said this is a promising…

Source: www.labiotech.euRead more